{"id":"cs-3150","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CS-3150 selectively antagonizes the mineralocorticoid receptor, preventing aldosterone-mediated sodium reabsorption and potassium excretion in the kidney. This leads to natriuresis, reduced fluid volume, and decreased blood pressure. It is designed to have improved selectivity for the MR over other steroid receptors compared to earlier-generation MR antagonists, potentially reducing off-target effects.","oneSentence":"CS-3150 is a non-steroidal mineralocorticoid receptor (MR) antagonist that blocks aldosterone signaling to reduce sodium retention and blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:31.004Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with preserved ejection fraction (HFpEF)"}]},"trialDetails":[{"nctId":"NCT02345044","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-01","conditions":"Essential Hypertension","enrollment":426},{"nctId":"NCT02448628","phase":"PHASE2","title":"A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-05","conditions":"Hypertension","enrollment":33},{"nctId":"NCT02722265","phase":"PHASE3","title":"Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-03","conditions":"Essential Hypertension","enrollment":368},{"nctId":"NCT04019652","phase":"PHASE1","title":"The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-11-19","conditions":"Hypertension, Mineralocorticoid Receptor Antagonist","enrollment":55},{"nctId":"NCT02848170","phase":"NA","title":"Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-08","conditions":"Essential Hypertension","enrollment":40},{"nctId":"NCT02807974","phase":"PHASE3","title":"Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-06","conditions":"Hypertension","enrollment":51},{"nctId":"NCT02890173","phase":"PHASE3","title":"Study of CS-3150 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-09","conditions":"Essential Hypertension","enrollment":1001},{"nctId":"NCT02808026","phase":"PHASE3","title":"Study of CS-3150 in Patients With Severe Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-06","conditions":"Severe Hypertension","enrollment":20},{"nctId":"NCT02885662","phase":"NA","title":"Study of CS-3150 in Patients With Primary Aldosteronism","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-09","conditions":"Primary Aldosteronism","enrollment":44},{"nctId":"NCT02345057","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-01","conditions":"Diabetic Nephropathy","enrollment":365},{"nctId":"NCT02807987","phase":"PHASE3","title":"Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-06","conditions":"Hypertension With Moderate Renal Impairment","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Esaxerenone"],"phase":"phase_3","status":"active","brandName":"CS-3150","genericName":"CS-3150","companyName":"Daiichi Sankyo Co., Ltd.","companyId":"daiichi-sankyo-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CS-3150 is a non-steroidal mineralocorticoid receptor (MR) antagonist that blocks aldosterone signaling to reduce sodium retention and blood pressure. Used for Hypertension, Heart failure with preserved ejection fraction (HFpEF).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}